• TBXA2R–ERM Signaling Drives Metastasis in Triple-Negative Br

  2026-06-26

  This study reveals that the thromboxane A2 receptor (TBXA2R), a G protein–coupled receptor, directly activates ezrin, radixin, and moesin (ERM) proteins to promote motility, invasion, and metastatic colonization of triple-negative breast cancer (TNBC) cells. These findings highlight a previously uncharacterized signaling axis central to metastatic progression and present new opportunities for targeted research in cancer metastasis.

• P2Y2 Receptor Activation Drives Microglial Aβ1–42 Uptake and

  2026-06-26

  Kim et al. (2012) demonstrated that nucleotides released from microglia exposed to Amyloid β-Peptide (1-42) (Aβ42) enhance neighboring microglial migration and Aβ42 uptake via P2Y2 receptor activation. These findings clarify a pivotal mechanism for amyloid clearance in Alzheimer's disease, opening new avenues for therapeutic targeting of innate immune pathways.

• Oligo (dT) 25 Beads: Protocols for Reliable mRNA Isolation

  2026-06-25

  Oligo (dT) 25 Beads enable rapid, high-purity isolation of eukaryotic mRNA from total RNA or lysates by leveraging specific polyA tail capture. They are best suited for workflows requiring intact mRNA, such as RT-PCR, first-strand cDNA synthesis, and sequencing. Not recommended for non-polyadenylated RNA or prokaryotic samples.

• CFDA SE Cell Tracer Kit: Technical Use and Workflow Guide

  2026-06-25

  The CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Cell Tracer Kit enables stable, long-term fluorescent labeling for cell proliferation and lineage tracing in both in vitro and in vivo research. Its persistent covalent labeling is ideal for applications requiring long-term cell tracking but is not suitable for reversible or real-time physiological monitoring. Researchers should avoid using this kit for workflows needing short-term or reversible cell labeling.

• Chloroquine Diphosphate: Optimizing Autophagy Assays in Canc

  2026-06-24

  Chloroquine diphosphate stands apart as a dual-function autophagy modulator and TLR7/9 inhibitor, enabling advanced tumor cell and therapy resistance studies. This guide delivers actionable workflows, troubleshooting, and key innovations that empower reproducible, translational cancer research.

• Vitamin C (CAS 50-81-7): Redefining Anticancer and Senescenc

  2026-06-23

  Explore how Vitamin C (ascorbic acid) advances cancer research as an apoptosis inducer and anti-senescence agent. This article uniquely bridges molecular mechanisms with practical assay guidance, offering new insights beyond conventional protocols.

• Fingolimod (FTY720): Precision Immunomodulation in Modern Im

  2026-06-23

  Explore how Fingolimod (FTY720) is revolutionizing immune modulation and neuroprotection in multiple sclerosis and advanced in vivo T cell engineering. Discover distinct mechanistic insights and practical protocols that set this cornerstone apart from previous coverage.

• Protease Inhibitor Cocktail (100X in DMSO, EDTA plus): Relia

  2026-06-22

  This article delivers a scenario-driven, evidence-based guide for biomedical researchers facing protein degradation in cell viability, proliferation, and cytotoxicity assays. Using SKU K1019, the Protease Inhibitor Cocktail (100X in DMSO, EDTA plus), we explore real laboratory challenges and validated solutions, highlighting workflow compatibility, protocol optimization, and data reproducibility.

• Angiotensin II–HIF-1α-HILPDA Axis Drives NPC Radioresistance

  2026-06-22

  This study uncovers how local angiotensin II (Ang II) promotes radioresistance in nasopharyngeal carcinoma (NPC) by suppressing ferroptosis through the HIF-1α–HILPDA axis. The findings reveal a positive feedback loop involving AGT and HIF-1α, suggesting that targeting the Ang II pathway and ferroptosis could enhance radiosensitivity and improve therapeutic outcomes in NPC.

• Dacomitinib (PF-00299804): Applied Workflows in Cancer Resea

  2026-06-21

  Explore how Dacomitinib (PF-00299804) empowers precise dissection of ErbB signaling, apoptosis, and cell cycle control in resistant cancer models. This guide details practical protocols, advanced applications, and troubleshooting strategies to maximize reproducibility and impact in translational oncology research.

• Nullscript: Precision Histone Deacetylase Inhibitor for Card

  2026-06-20

  Nullscript stands out among HDAC inhibitors with its selective inactivity in transcriptional facilitation and robust in vivo efficacy for reducing myocardial infarct size. This guide details applied workflows, data-driven protocol enhancements, and troubleshooting tactics to maximize Nullscript’s research value in cardiac, neurodegenerative, and cancer models.

• Optimized hiPSC Platelet Differentiation: Small Molecule Adv

  2026-06-19

  This study presents a refined protocol for producing functional platelets from human induced pluripotent stem cells (hiPSCs), emphasizing small molecule substitutions and culture optimization. The findings highlight a substantial increase in yield and cost-effectiveness, establishing a foundation for scalable cell therapy and translational research.

• Fosinopril Sodium: Optimizing ACE Inhibitor Workflows in Hyp

  2026-06-19

  Fosinopril sodium’s phosphinic acid structure and dual excretion profile enable precise, reproducible hypertension and cardiovascular disease modeling. This guide details hands-on protocol insights, troubleshooting strategies, and the translational advantages of using APExBIO’s Fosinopril sodium for advanced ACE inhibitor studies.

• Weight Loss Restores Gut Stretch-Induced Satiety in Obesity

  2026-06-18

  This study demonstrates that obesity impairs the suppressive effects of intestinal stretch on food intake and glucose metabolism, but both dietary and surgical weight loss can restore these mechanisms. The findings refine our understanding of mechanosensory regulation of satiety, independent of classical incretin pathways, and have important implications for metabolic disease research.

• Breast Cancer’s Dependence on MCL-1: Apoptotic Mechanisms an

  2026-06-18

  The reference study demonstrates that breast cancer cells depend on MCL-1 primarily for its canonical anti-apoptotic activity, rather than non-apoptotic roles. These findings clarify the mechanistic rationale for targeting MCL-1 and related pathways in breast cancer, with implications for designing more effective apoptosis-inducing therapeutic strategies.

15438 records 1/1030 page Next 12345 下5页 Last page